RealWire Limited

Delivering Relevance, Releasing Influence

Issue Date

Images
Molecular Profiles
Molecular Profiles
view
Dr. Rob Whittock, Associate Director of Materials Characterisation, Molecular Profiles
Dr. Rob Whittock, Associate Director of Materials Characterisation, Molecular Profiles
view
New addition to the Scientific Panel at Molecular Profiles, Lisbeth Illum.
New addition to the Scientific Panel at Molecular Profiles, Lisbeth Illum.
view

Release Feed
RSS FeedMolecular Profiles Feed
Share Release
Tweet Facebook LinkedIn Digg This
blink it Reddit! Stumble It! Add to Diigo Bookmark this on Delicious
Tweet Facebook LinkedIn
Press Release

Molecular Profiles Enhances Team with Specialist Pharmaceutical Patent Litigation Support and new Addition to Scientific Panel

(Nottingham, UK, 14 January 2008) – Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide, announces the appointment of Dr. Rob Whittock as Associate Director of Materials Characterisation.  Based in Nottingham, he will provide technical direction and leadership to the materials characterisation team and support independent experts across the UK, Europe and USA; and clients’ scientific staff, Patent Attorneys and in-house Patent Counsel.

Dr. Rob Whittock holds a PhD in Physical Organic Chemistry and previously worked as a Senior Scientist at AstraZeneca, where he gained a wealth of experience in pharmaceutical R&D, particularly in solid state characterisation (Polymorphism) and the developability assessment of new candidate drugs. In addition to his interest in solid state characterization he has a strong interest in intellectual property law, and has undertaken a post graduate diploma in Law at Nottingham Law School and the Bar Vocational Course at BPP Law School, London.

Molecular Profiles also announces the expansion of its Scientific Panel with the appointment of industry guru Professor Lisbeth Illum. The Scientific Panel complements the intellectual property, patent litigation support and contract research services already offered by Molecular Profiles to the pharmaceutical and biomedical industries.

Professor Lisbeth Illum has over 25 years’ experience in the pharmaceutical industry, and has held a variety of academic, editorial and professional positions including consulting to several multinational pharmaceutical companies. Among the top 100 most-cited scientists on pharmacology, Illum has published more than 300 scientific papers and has filed nearly 50 patents on novel drug delivery systems. Professor Illum will also be the President of the Controlled Release Society in 2008.

Molecular Profiles’ services can be broadly categorised into three key areas: formulation support (including pre-formulation and product R&D); rapid problem solving (during pre-formulation right through to manufacturing); and patent and litigation support. Molecular Profiles have a range of expert witnesses who lead multidisciplinary teams that can attest to international experience of deposition and trial testimony in support of litigation issues.

“Over the years we have grown organically, by reinvesting in the latest technology, developing new analytical methodologies and expanding our services”, comments Dr. Nikin Patel, CEO, Molecular Profiles. “Our services and technology are extremely innovative and we are delighted to welcome  Rob and Lisbeth to the team.”

More information about Molecular Profiles’ award-winning services is available at www.molprofiles.co.uk, by e-mail at enquiry@molprofiles.co.uk, alternatively, call Dr. Nikin Patel on +44 115 8718880.
 
###

About Molecular Profiles

Molecular Profiles is a leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide. The company is a recipient of a Queen’s Award for Enterprise in the Continuous Innovation and Development category. The award saw the company and its complete range of services recognised as one of the UK’s most innovative during 2007. The services include nanoscreening technology for predicting the ease of development of a new medicine, a deformulation service for identifying problems with a product down to the nanoscale, and advanced imaging for viewing and optimising the internal structure of products.